Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 12/20 | 0.71 |
| ▸ | LDHB | P07195 | 11/20 | 0.71 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | TRPM7 | Q96QT4 | 1/20 | 0.34 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL235873 | 0.84 | LDHA (1.00) | LDHALDHBALBPTPN1PTPN11 | |
| SCHEMBL233361 | 0.81 | LDHA (1.00) | LDHALDHBPTPN1PTPN2 | |
| SCHEMBL30417934 | 0.81 | LDHA (1.00) | LDHALDHBPTPN1PTPN2 | |
| SCHEMBL7179530 | 0.79 | LDHA (0.87) | LDHALDHBALB | |
| SCHEMBL7187931 | 0.79 | LDHA (0.87) | LDHALDHBALB | |
| SCHEMBL7185727 | 0.74 | LDHA (0.78) | LDHALDHBPPARGPPARA | |
| SCHEMBL7174623 | 0.72 | LDHA (1.00) | LDHALDHBALBPTPN1PTPN11 | |
| SCHEMBL15322250 | 0.71 | LDHA (0.82) | LDHALDHBPTPN1PTPN2 | |
| SCHEMBL15841763 | 0.65 | LDHA (0.59) | LDHALDHBPTPN1PTPN11PTPN2 | |
| SCHEMBL7186222 | 0.64 | LDHA (0.62) | LDHALDHBPTPN1PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120003156-A1 | METHODS FOR TREATING NEOPLASIA BY INHIBITING LACTATE DEHYDROGENASE AND/OR NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120003156-A1 | METHODS FOR TREATING NEOPLASIA BY INHIBITING LACTATE DEHYDROGENASE AND/OR NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2010002465-A2 | METHODS FOR TREATING NEOPLASIA BY INHIBITING LACTATE DEHYDROGENASE AND/OR NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003156-A1 | METHODS FOR TREATING NEOPLASIA BY INHIBITING LACTATE DEHYDROGENASE AND/OR NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | NAMPT, NAPRT, NNT | LDHA 9/4885LDHB 6/4885ALB 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.